QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. The company’s automated systems and its consumable products empower customers to transform raw biological samples into valuable molecular insights. Sample technologies are used to isolate DNA (deoxyribonucleic acid), RNA (ribonucleic acid) and proteins from any biological sample, such as blood or tissue as well as plants and other samples that contain biological materials. Products The company offers approximately 500 core consumable products (known as ‘kits’), as well as various instrument solutions to automate the processing of its products used for sample preparation, analysis and interpretation. Sample Technologies: The company has developed and advanced a range of technologies to extract and purify molecules of interest from biological samples such as blood, bone, tissue, etc. Assay Technologies: Assay technologies make information contained in isolated molecules visible and available for interpretation. Laboratory-Developed Test (LDT) assays enable the customer to target molecules of interest for detection using reagents in the kit on platforms such as polymerase chain reaction (PCR). Commercially approved assays are preconfigured by the company to test for specific targets, such as genetic mutations, gene expression levels, influenza, human papillomavirus (HPV), tuberculosis (TB), hepatitis, herpes virus or human immunodeficiency virus (HIV). These technologies provide two main categories of revenue streams for the company: Consumables and related sales: Consumable products are sample preparation or test kits and related products. Each kit is sufficient to support various applications, varying from 1 to approximately 1,000 tests. Major applications for its consumable products are plasmid DNA purification, RNA purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; PCR amplification; reverse transcription; DNA cleanup after PCR and sequencing; DNA cloning and protein purification. The company’s validated PCR assays enable detection of viral or bacterial pathogens and parasites in humans and animals, as well as pharmacogenomic testing and genotyping. Automation platforms and instruments: The company’s instrumentation systems, automate the use of sample and assay technologies into solutions for a range of laboratory needs. These enable customers to perform processes, such as nucleic acid sample preparation, assay setup, target detection as well as complete workflow solutions. The company offers automated platforms for all phases of testing, from sample to result. These are as follows: QIAsymphony is a modular system that is making laboratory workflows efficient and helps to disseminate standardized, regulator-approved diagnostics. In 2013, the installed base of QIAsymphony systems was approximately 1,000 instruments worldwide. The platform offers various features of interest to laboratories, such as continuous loading, random access, and the ability to process an almost unlimited range of sample types. Rotor-Gene Q is a rotary real-time PCR cycler system, using real-time PCR reactions to make specific sequences of DNA and RNA visible through amplification and quantifiable through real-time measurement. PyroMark is a high-resolution detection platform based upon Pyrosequencing technology that allows for the real-time analysis and quantification of genetic mutations and DNA methylation patterns down to the single base pair level. QIAcube is a sample processing instrument incorporating novel and proprietary technologies that allows users to fully automate the use of almost all of its products originally designed for manual processing of samples. QIAxcel is designed to replace traditional slab-gel analysis, eliminating various methods of nucleic acid separation in low- to high-throughput laboratories. ESE-Quant Tube Scanners are portable, battery-operated optical measurement devices based on technology developed by ESE GmbH. These UV and fluorescence detection systems enable point of need testing in healthcare and applied testing markets.
qiagen n.v. (QIA:XETRA)
Venlo, 5911 KJ
Phone: 31 77 320 8400
Fax: 31 77 320 8409www.qiagen.com
|Bio-Reference Laboratories Inc||$35.23 USD||+0.22|
|Myriad Genetics Inc||$33.59 USD||-0.77|
|PerkinElmer Inc||$51.65 USD||+0.08|
|View Industry Companies|
Sponsored Financial Commentaries
To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.